Keyphrases
Chemotherapy
100%
Adjuvant Therapy
100%
Cisplatin
100%
Radiotherapy
100%
Chemoradiation
100%
Phase I Trial
100%
WEE1
100%
Trial Protocol
100%
Head-and-neck Cancer
100%
Window of Opportunity Trials
100%
DNA Damage
66%
Recommended Dose
66%
AZD1775
66%
High Risk
33%
Clinical Outcomes
33%
Peer-reviewed Publication
33%
Research Ethics Committees
33%
International Conference
33%
Quality of Life
33%
Pharmacodynamic Interactions
33%
Dose Finding
33%
Continual Reassessment Method
33%
Therapeutic Effect
33%
Overall Survival
33%
Edgbaston
33%
West Midlands
33%
Research Ethics
33%
Safe Dose
33%
Potential Biomarkers
33%
Kinase Inhibitor
33%
Biological Response
33%
Adavosertib
33%
Cure Rate
33%
Dose-limiting Toxicity
33%
Pharmacodynamic Markers
33%
Kinase Inhibition
33%
Cisplatin-based Chemotherapy
33%
Cell Cycle Checkpoint
33%
Target Dose
33%
Combined Modality Therapy
33%
Dissemination Research
33%
Disease-free Survival
33%
WEE1 Kinase
33%
Time-to-event
33%
Checkpoint Kinase 1 (CHK1)
33%
Multicenter Trial
33%
Surgical Complications
33%
Pathological Features
33%
Quality of Life Impact
33%
Resection Status
33%
Concurrent Chemotherapy
33%
Adjuvant Radiotherapy
33%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
33%
Negative Impact
33%
Locally Advanced Disease
33%
Wee1 Inhibitors
33%
Medicine and Dentistry
Adjuvant Therapy
100%
Phase I Trials
100%
Radiation Therapy
100%
Cisplatin
100%
Head and Neck Cancer
100%
Chemoradiotherapy
75%
Adavosertib
75%
Quality of Life
50%
Pharmacodynamics
50%
Recommended Drug Dose
50%
Disease
25%
Biological Marker
25%
Overall Survival
25%
Surgery
25%
Phosphotransferase Inhibitor
25%
Survival Time
25%
Disease Free Survival
25%
DNA Damage Response
25%
Therapy Effect
25%
Head and Neck Squamous Cell Carcinoma
25%
Cell Cycle Checkpoint
25%
Adjuvant Radiotherapy
25%
Phosphotransferase
25%
DNA Damage
25%
Postoperative Complication
25%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Cisplatin
100%
Phase I Trials
100%
Head and Neck Cancer
100%
Chemoradiation Therapy
75%
Adavosertib
75%
Pharmacodynamics
50%
Disease
25%
Biological Marker
25%
Therapeutic Effect
25%
Overall Survival
25%
Phosphotransferase Inhibitor
25%
Head and Neck Squamous Cell Carcinoma
25%
Phosphotransferase
25%
Postoperative Complication
25%
Disease Free Survival
25%
Survival Time
25%